InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,462.18
(
0.26%
)
US TECH 100
19,114.00
(
0.82%
)
Dow Jones
39,102.57
(
-0.78%
)
Brent Oil
84.59
(
-0.80%
)
Bitcoin
61,532.30
(
2.10%
)
Post# of 252340
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

anesthesia doc

Send PM Follow Ignore
Followers 5
Posts 171
Boards Moderated 0
Alias Born 08/25/2010

anesthesia doc

Member Level

Re: DewDiligence post# 173521

Friday, 01/31/2014 8:00:20 AM

Friday, January 31, 2014 8:00:20 AM

Post# of 252340
Enanta Pharmaceuticals Announces Results from Four All-Oral, Interferon-Free, Phase 3 Studies for the Treatment of Genotype 1 Hepatitis C Virus Infection

http://finance.yahoo.com/news/enanta-pharmaceuticals-announces-results-four-124400458.html

Enanta Pharmaceuticals Announces Results from Four All-Oral, Interferon-Free, Phase 3 Studies for the Treatment of Genotype 1 Hepatitis C Virus Infection
Results confirm previously reported data in genotype 1 (GT1) patient populations demonstrating high sustained virologic response rates at 12 weeks post-treatment (SVR12)
Results demonstrate SVR12 of 97 to 100% in GT1b patients
SVR12 of 92 to 96% was shown in the difficult-to-treat GT1 cirrhotic patient population
AbbVie announced it expects U.S. launch in 2014
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up